Exoplanet's Winds 'Challenge Our Understanding of How Weather Works'
"It feels like something out of science fiction," said European Southern Observatory astrophysicist Julia Victoria Seidel.
Stocktwits on MSN8d
Vertex Pharma Stock Flooded With Price-Target Hikes After Upbeat Q4 Revenue, 2025 Outlook: Retail Stays Bullish
Shares of Vertex Pharmaceuticals, Inc. were in the spotlight in premarket trading Tuesday as the biotech company received ...
The Tesla Model Y Juniper's Big Changes, Explained By Its Designer
It’s been over two weeks since Tesla unexpectedly unveiled the heavily revised version of its Model Y crossover known as ...
Vertex Pharma Just Scored a Major FDA Approval. Is the Stock a No-Brainer Buy Now?
Vertex Pharmaceuticals ( VRTX 2.53%) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs ...
Vertex Sec Consolidated December 2024 Net Sales at Rs 1.80 crore, down 7.73% Y-o-Y
Net Sales at Rs 1.80 crore in December 2024 down 7.73% from Rs. 1.95 crore in December 2023. Quarterly Net Loss at Rs. 0.44 crore in December 2024 down 1052.48% from Rs. 0.05 crore in December 2023.
Wall Street Journal18d
Vertex Pharmaceuticals Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
MedCity News19d
Vertex Pharma’s Opioid Alternative Wins FDA Approval, First in a New Class of Pain Meds
A novel Vertex Pharmaceuticals drug that takes a new approach to pain is now approved by the FDA, a landmark decision for a first-in-class product that brings patients a treatment alternative ...
Dayton Daily News19d
FDA approves painkiller designed to eliminate the risk of addiction associated with opioids
The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals' Journavx for short-term pain that often follows surgery or injuries. It’s the first new pharmaceutical approach to ...
Hosted on MSN20d
Vertex Pharmaceuticals' SWOT analysis: stock poised for growth amid pipeline expansion
Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company with a market capitalization of $113.7 billion, is navigating a critical juncture as it seeks to expand its therapeutic reach ...
The Huntsville Item20d
Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVX™ (suzetrigine), an oral, non-opioid, highly selective ...